Torbay Hospital first in UK to offer pioneering prostate cancer trial


Torbay Hospital is the first site to open the MK2400-001 trial in the UK and the first to recruit a UK patient, with researchers hoping the new targeted treatment will improve outcomes and quality of life for patients with advanced prostate cancer.
Torbay Hospital has become the first site in the UK to open a pioneering international research trial investigating a new treatment for advanced prostate cancer, with four patients now taking part.
The trial, known as MK2400-001, will be evaluating whether a target drug, called ifinatamab deruxtecan (MK-2400), could offer an alternative to chemotherapy for patients whose prostate cancer is continuing to spread despite hormone treatment.
The trial closes for recruitment in August 2027.
Researchers will be investigating whether the drug helps patients live longer by slowing the progression of the disease, as well as reducing some of the debilitating side effects associated with chemotherapy.
The treatment is designed to target a protein found on prostate cancer cells, delivering it straight to the tumour cells, unlike chemotherapy which affects both cancerous and healthy cells and can damage healthy tissue.
Dominic Gover is one of the patients on the trial and has reflected on his experience so far.
He said: “I was first diagnosed in 2018 and it was Dr Lydon who told me about the trial earlier this year. When I was asked if I’d like to be involved, I didn’t let Dr Lydon finish the sentence – I said yes immediately!”
“I started treatment in July and was both excited and anxious, but the team has been so supportive.”
“When I think about my previous treatment and how unwell it made me feel because it attacks everything, I’m hoping this new targeted treatment will have fewer side effects. If everything goes well, I can continue having the treatment indefinitely, which is much longer than the usual standard of care drug.”
“It feels like a positive experience has come out of a negative situation and I’m just grateful for the opportunity.”
Researchers behind the trial are hoping that this more targeted approach could improve the outcomes and quality of life for patients with advanced prostate cancer.
Dr Anna Lydon, Clinical Oncologist at Torbay and South Devon NHS Foundation Trust and the trial’s Principal Investigator said: “We are always trying to offer patients treatments that don't upset their daily living unduly and this trial drug offers the real hope of that.”
“We are so pleased to have this trial available to our patients in Torbay and South Devon and are very grateful to those men who are taking part.”